Literature DB >> 32107165

Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity.

Anupam Karki1, Reecan Juarez2, Hari K Namballa2, Ian Alberts3, Wayne W Harding4.   

Abstract

New aporphines containing C10 nitrogen substituents (viz. nitro, aniline or amide moieties), were synthesized and evaluated for affinity at human serotonin 5-HT1A and 5-HT2A receptors and at human dopamine D1, D2 and D5 receptors. Two series of analogs were investigated: series A which contain a sole C10 nitrogen substituent on the tetracyclic aporphine core and series B which are 1,2,10-trisubstituted aporphines. Remarkably, compounds from both series lacked affinity for the D5 receptor, thus attaining D1 versus D5 selectivity. Compound 20c was the most potent D1 ligand identified. Docking studies at D1 and D5 receptors indicate that the binding mode of 20c at the D1 receptor allows for stronger hydrophobic contacts, (primarily with Phe residues) as compared to the D5 receptor, accounting for its D1 versus D5 selectivity. Considering the lack of affinity for the D5 receptor (and low affinity at other receptors tested), compound 20c represents an interesting starting point for further structural diversification of aporphines as sub-type selective D1 receptor tools.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aporphine; D(1) receptor; D(5) receptor; Dopamine; Serotonin

Mesh:

Substances:

Year:  2020        PMID: 32107165      PMCID: PMC7067653          DOI: 10.1016/j.bmcl.2020.127053

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  40 in total

1.  Effects of chronic administration of the D1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys.

Authors:  Nicole H Mutschler; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2002-02-12       Impact factor: 4.530

2.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

Authors:  Vadim Cherezov; Daniel M Rosenbaum; Michael A Hanson; Søren G F Rasmussen; Foon Sun Thian; Tong Sun Kobilka; Hee-Jung Choi; Peter Kuhn; William I Weis; Brian K Kobilka; Raymond C Stevens
Journal:  Science       Date:  2007-10-25       Impact factor: 47.728

3.  (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.

Authors:  Rui Zhao; Weijian Lu; Xing Fang; Lin Guo; Zhi Yang; Na Ye; Jiahao Zhao; Zhili Liu; Jia Jia; Longtai Zheng; Bin Zhao; Ao Zhang; Xuechu Zhen
Journal:  Pharmacol Biochem Behav       Date:  2014-06-21       Impact factor: 3.533

4.  Differential effects of D1 and D2 dopamine agonists on stereotyped locomotion in rats.

Authors:  D Eilam; K V Clements; H Szechtman
Journal:  Behav Brain Res       Date:  1991-11-26       Impact factor: 3.332

5.  Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.

Authors:  Mark J Millan; Lisa Maiofiss; Didier Cussac; Valérie Audinot; Jean-A Boutin; Adrian Newman-Tancredi
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

6.  Further SAR study on 11-O-substituted aporphine analogues: identification of highly potent dopamine D3 receptor ligands.

Authors:  Na Ye; QianQian Wu; Liyuan Zhu; Longtai Zheng; Bo Gao; Xuechu Zhen; Ao Zhang
Journal:  Bioorg Med Chem       Date:  2011-01-31       Impact factor: 3.641

Review 7.  Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.

Authors:  Tove Henriksen
Journal:  Neurodegener Dis Manag       Date:  2014

Review 8.  An overview on benzylisoquinoline derivatives with dopaminergic and serotonergic activities.

Authors:  N Cabedo; I Berenguer; B Figadère; D Cortes
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 9.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.

Authors:  P J Blanchet; J Fang; M Gillespie; L Sabounjian; K W Locke; R Gammans; M M Mouradian; T N Chase
Journal:  Clin Neuropharmacol       Date:  1998 Nov-Dec       Impact factor: 1.592

View more
  1 in total

1.  Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT7AR ligands.

Authors:  Anupam Karki; Hari K Namballa; Ian Alberts; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2020-06-05       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.